Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1137-1142

  Suga, Yasuhiro ^a   Miyajima, Kuniharu ^a   Oikawa, Takefumi ^a   Meada, Junichi ^a   Usuda, Jitsuo ^a   Kajiwara, Naohiro ^a   Ohira, Tatsuo ^a   Uchida, Osamu ^a   Tsuboi, Masahiro ^a   Hirano, Takashi ^a   Kato, Harubumi ^a   Ikeda, Norihiko ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

ESR1; Methylation; Non small cell lung cancer; p16; Real time PCR

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; DNA; ESTROGEN RECEPTOR; PROTEIN ESR1; PROTEIN P16; UNCLASSIFIED DRUG; ESR1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BENIGN TUMOR; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENETIC CORRELATION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; AGE; BLOOD; BLOOD EXAMINATION; GENETICS; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR SUPPRESSOR GENE;

AGE FACTORS; AGED; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENES, P16; HEMATOLOGIC TESTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 58149357596     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000121     Document Type: Article

References (29)

1. An Q, Liu Y, Gao Y, Huang J, Fong X, Li L, Zhang D and Cheng S: Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett 188: 109-114, 2002.
2. Esteller M, Sanchez-Cespedes M, Rosell, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70, 1999.
3. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J and Sidransky D: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91: 332-339, 1999.
4. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA and Crowell RE: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377, 2002.
5. Ng CS, Zhang J, Wan S, Lee TW, Arifi AA, Mok T, Lo DY and Yim AP: Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 79: 101-106, 2002.
6. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, Holscher AH, Meltzer SJ and Danenberg PV: Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528-3532, 2001.
7. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano JA and Sidransky D: Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64: 5511-5517, 2004.
8. Wong IH, Zhang J, Lai PB, Lau WY and Lo YM: Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 9: 1047-1052, 2003.
9. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB and Herman JG: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896, 1998.
10. Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, Kaufmann SH and Baylin SB: The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 53: 973-977, 1996.
11. Lai JC, Cheng YW, Chiou HL, Wu MF, Chen CY and Lee H: Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer 117: 974-980, 2005.
12. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7: 536-540, 1994.
13. Zajchowski DA, Sager R and Webster L: Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 53: 5004-5011, 1993.
14. Issa JP, Baylin SB and Belinsky SA: Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 56: 3655-3658, 1996.
15. Marchevsky AM, Tsou JA and Laird-Offringa IA: Classification of individual lung cancer cell lines based on DNA methylation markers: use of linear discriminant analysis and artificial neural networks. J Mol Diagn 6: 28-36, 2004.
16. Lapidus, RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP and Davidson NE: Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2: 805-810, 1996.
17. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB and Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555, 1994.
18. Herman JG, Graff JR, Myohanen S, Hamilton SR, Nelkin BD and Baylin SB: Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
19. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA and Laird PW: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61: 3410-3418, 2001.
20. Toyooka KO, Toyooka S, Maitra A, Feng Q, Kiviat NC, Smith A, Minna JD, Ashfaq R and Gazdar AF: Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol 161: 629-634, 2002.
21. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG and Brock MV: Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 10: 5131-5136, 2004.
22. Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet 21: 163-167, 1999.
23. Ikeda N, MacAulay C, Lam S, LeRiche J, Payne P, Garner D, Konaka C, Kato H and Palcic B: Malignancy associated changes in bronchial epithelial cells and clinical application as a biomarker. Lung Cancer 19: 161-166, 1998.
24. Ulivi P, Zoli W, Calistri D, Fabbri F, Tesei A, Rosetti M, Mengozzi M and Amadori D: p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 206: 611-615, 2006.
25. Issa JP, Vertino PM, Boehm CD, Newsham IF and Baylin SB: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 93: 11757-11762, 1996.
26. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG and Brock MV: Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res 10: 7917-7924, 2004.
27. Shao ZM and Guyen MN: Tumor-specific DNA in plasma of breast cancer patients. Anticancer Drugs 13: 353-357, 2002.
28. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M and Hamajima N: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
29. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360, 2004.